Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NYSE | Common Stock
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally.
The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief.
The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products.
It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels.
The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018.
Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
As of February 6, 2004, Prestige Consumer Healthcare Inc. was taken private.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | 0.98 Increased by +120.29% | 1.14 Decreased by -14.04% |
| Feb 8, 24 | 1.06 Increased by +1.92% | 1.04 Increased by +1.92% |
| Nov 2, 23 | 1.07 Increased by +4.90% | 1.07 |
| Aug 3, 23 | 1.06 Decreased by -2.75% | 1.01 Increased by +4.95% |
| May 4, 23 | -4.83 Decreased by -630.77% | 1.04 Decreased by -564.42% |
| Feb 2, 23 | 1.04 Increased by +5.05% | 1.01 Increased by +2.97% |
| Nov 3, 22 | 1.02 Increased by 0.00% | 1.00 Increased by +2.00% |
| Aug 4, 22 | 1.09 Decreased by -4.39% | 1.04 Increased by +4.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 286.32 M Decreased by -1.02% | 53.56 M Increased by +4.97% | Increased by +18.71% Increased by +6.05% |
| Jun 30, 23 | 279.31 M Increased by +0.81% | 53.28 M Decreased by -3.61% | Increased by +19.07% Decreased by -4.39% |
| Mar 31, 23 | 285.87 M Increased by +7.09% | -240.55 M Decreased by -561.84% | Decreased by -84.15% Decreased by -531.25% |
| Dec 31, 22 | 275.52 M Increased by +0.38% | 51.95 M Increased by +3.46% | Increased by +18.86% Increased by +3.06% |
| Sep 30, 22 | 289.27 M Increased by +4.72% | 51.02 M Increased by +12.57% | Increased by +17.64% Increased by +7.49% |
| Jun 30, 22 | 277.06 M Increased by +2.93% | 55.27 M Decreased by -4.30% | Increased by +19.95% Decreased by -7.02% |
| Mar 31, 22 | 266.94 M Increased by +12.27% | 52.09 M Increased by +46.66% | Increased by +19.51% Increased by +30.63% |
| Dec 31, 21 | 274.47 M Increased by +14.94% | 50.22 M Increased by +22.86% | Increased by +18.30% Increased by +6.88% |